Kindred Biosciences (NYSE:KIN) was downgraded by stock analysts at Roth Capital from a “buy” rating to a “neutral” rating in a report issued on Friday, TheFlyOnTheWall.com reports. They currently have a $25.00 price target on the stock, up from their previous price target of $20.00. Roth Capital’s price objective points to a potential upside of 2.46% from the company’s current price. Kindred Biosciences Inc (NASDAQ:KIN) weekly performance is -1.38%. On last trading day company shares ended up $24.24. Kindred Biosciences Inc (NASDAQ:KIN) distance from 50-day simple moving average (SMA50) is 33.19%. Analysts mean target price for the company is $28.67.
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced that new in vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented during a poster session at the 21st Conference on Retroviruses and Opportunistic Infections in Boston. Designed to enable once-daily dosing without ritonavir, ABT-493 is expected to be co-formulated with AbbVie’s (ABBV) next-generation NS5A inhibitor, ABT-530. Data from poster demonstrates that ABT-493 has a “substantially improved in vitro profile compared to earlier generation HCV NS3/4A protease inhibitors and displays potent and broad genotypic activity in genotypes 1a, 1b, 2a, 3a, 4a and 6a, against which many other HCV NS3/4A protease inhibitors have significantly lower potency”, the company said. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) shares advanced 7.11% in last trading session and ended the day on $40.85. ENTA return on equity ratio is recorded as -12.20% and its return on assets is -11.60%.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)reported fourth quarter 2013 net loss per share of 23 cents, flat year over year. The reported loss was wider than the Zacks Consensus Estimate of a loss of 18 cents. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares moved up 0.68% in last trading session and was closed at $17.65, while trading in range of $16.79 – $18.13. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) year to date (YTD) performance is 42.22%.
Synthetic Biologics Inc (NYSEMKT:SYN) announced that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California. The patent includes claims to the use of the company’s drug candidate, Trimesta in conjunction with a gestagen for the treatment of multiple sclerosis and other autoimmune diseases. The patent also includes a claim for the administration of Trimesta, a gestagen and a third standard of care MS agent, such as glatiramer acetate injection Copaxone, interferon beta-1a, Avonex, Rebif, interferon beta-1b, Betaseron, Extavia, or sphingosine-1-phosphate receptor modulator Gilenya. Synthetic Biologics Inc (NYSEMKT:SYN) shares after opening at $2.99 on last trade day and at the end of the day closed at $3.13. Company price to cash ratio in past twelve months was calculated as 27.41. Synthetic Biologics Inc (NYSEMKT:SYN) showed a positive weekly performance of 15.07%.